Caterpillar Arterial Embolization Device Post-Market Study

  • STATUS
    Recruiting
  • participants needed
    50
  • sponsor
    C. R. Bard
Send
Updated on 19 February 2024
See if I qualify

Summary

The primary objective of this study is to evaluate the performance and safety of the Caterpillar Arterial Embolization Device when used for arterial embolization in the peripheral vasculature in a real world, on-label application.

Description

The post-market study is a prospective, multi-center, single-arm, real world study of the Caterpillar Arterial Embolization Device. Enrollment will continue until up to fifty (50) subjects have been treated with the Caterpillar Arterial Embolization Device at up to 20 investigational sites in the United States.

Details
Condition Embolization
Age 18years - 100years
Treatment Caterpillar™ Arterial Embolization Device
Clinical Study IdentifierNCT04244370
SponsorC. R. Bard
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Subject or Legally Authorized Representative (LAR) must voluntarily sign and date the approved Informed Consent Form (ICF) prior to collection of study-specific data or performance of study-specific procedures
Subject must be either male or non-pregnant female 18 years of age with an expected lifespan sufficient to allow for completion of all study procedures
Subject must be willing and able to comply with protocol requirements, including all study visits and procedures
Subject must require peripheral vascular occlusion at an arterial target embolization site(s) that can be treated with the Caterpillar Arterial Embolization Device according to the Instructions for Use (IFU). Note: Per Investigator discretion, up to five (5) Target Embolization Sites may be treated with up to ten (10) study devices per subject
Angiographic Inclusion Criteria
\. The target embolization site(s) must be located in a native arterial
vessel(s) with the intended arterial vessel diameter ranges shown in the IFU
as assessed by the Investigator (via visual estimate)
\. The target embolization site(s) must have a landing zone sufficient to
accommodate the device implant lengths shown in the IFU

Exclusion Criteria

The subject's access vessel(s) preclude safe insertion of the delivery catheter
The subject's target embolization site(s) is located within a vein
The subject's target embolization site(s) is located within the head, neck, heart or coronary vessels
The subject's target embolization site(s) is located across highly locomotive joints or muscle beds (e.g. elbow, hip, knee, shoulder, thoracic inlet/outlet)
The subject's target embolization site(s) is located in a high-flow vessel where, in the opinion of the Investigator, there may be significant risk of migration and unintended (non-target site) occlusion
The subject has a known allergy or hypersensitivity to contrast media that cannot be adequately pre-medicated
The subject has a known allergy or hypersensitivity to any of the device materials including: cobalt, chromium, nickel, titanium, platinum, iridium, polyurethane or polyethylene
The subject has planned use of anticoagulant (e.g. direct thrombin inhibitors, factor Xa inhibitors, vitamin K antagonists) or antiplatelet therapy before, during and/or after treatment with the study device, which, in the opinion of the Investigator, would clinically interfere with the study endpoints
The subject has a known uncontrolled blood coagulation or bleeding disorder
The subject has an unresolved systemic infection
The subject's required pre-operative laboratory tests and/or physical examination indicate abnormal results, which, in the opinion of the Investigator, would clinically interfere with the study endpoints
The subject has a connective tissue disorders (e.g. Ehlers-Danlos Syndrome), arteritis (e.g. Takayasu's Disease) or another circulatory disorder, which, in the opinion of the Investigator, would clinically interfere with the study endpoints
The subject has another medical condition which, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, may confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up
The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.